Th17 and non-th17 interleukin-17-expressing cells in chronic lymphocyticleukemia: Delineation, distribution, and clinical relevance

Haematologica

Volumn 97, Issue 4, 2012, Pages 599-607

  Jain, Preetesh ^a,b   Javdan, Mohammad ^a   Feger, Franziska K ^a   Chiu, Pui Yan ^a   Sison, Cristina ^a   Damle, Rajendra N ^a,c   Bhuiya, Tawfiqul A ^c   Sen, Filiz ^c   Abruzzo, Lynne V ^d   Burger, Jan A ^d   Rosenwald, Andreas ^e   Allen, Steven L ^a,c,f   Kolitz, Jonathan E ^a,c,f   Rai, Kanti R ^a,c,f   Chiorazzi, Nicholas ^a,c,f,g   Sherry, Barbara ^a,c,f  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Northwell Health   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic lymphocytic leukemia; IL 17; Microenvironment; Myeloid differentiation; T lymphocyte; Th17

Indexed keywords

CD15 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; INTERLEUKIN 17; KI 67 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR;

ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAST CELL; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; SPLEEN CELL; TH17 CELL;

HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-17; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE COUNT; PROGNOSIS; SPLEEN; SURVIVAL ANALYSIS; TH17 CELLS;

EID: 84859465412     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047316     Document Type: Article

References (39)

1. Burger JA, Ghia P, Rosenwald A, Caligaris- Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
2. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2(12):933-944.
3. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from theT helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-1132.
4. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141.
5. Miossec P. Diseases that may benefit from manipulating the Th17 pathway. Eur J Immunol. 2009;39(3):667-669.
6. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556-567.
7. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, van Maldegem F, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499-508.
8. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med. 2007;204(5):995-1001.
9. Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17- producing CD8+ T cells. J Immunol. 2009; 182(9):5296-5305.
10. O'Brien RL, Roark CL, Born WK. IL-17- producing gammadelta T cells. Eur J Immunol. 2009;39(3):662-666.
11. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010; 184(7):3336-3340.
12. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8(9):942-949.
13. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957.
14. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898.
15. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol. 2009;5(6): 325-331.
16. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009; 183(7):4169-4175.
17. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumourmicroenvironment. Oncogene. 2010;29(42): 5653-5662.
18. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, et al. Tumor-infiltrating IL-17-producing gamma delta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 2010;40(7):1927-1937.
19. Jovcic G, Bugarski D, Krstic A, Vlaski M, Petakov M, Mojsilovic S, et al. The effect of interleukin-17 on hematopoietic cells and cytokine release in mouse spleen. Physiol Res. 2007;56(3):331-339.
20. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010;116(18):3554-3563.
21. Fossiez F, Djossou O, Chomarat P, Flores- Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593-2603.
22. Kao CY, Huang F, Chen Y, Thai P, Wachi S, Kim C, et al. Up-regulation of CC chemo- kine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol. 2005;175 (10):6676-6685.
23. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141-1149.
24. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer.2010;69(3):348-354.
25. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intra tumoral IL-17- producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50(5):980-989.
26. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 2008;112(7):2878-2885.
27. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385-5392.
28. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leu kaemia. Clin Exp Immunol. 2009;158(2):199-204.
29. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant β cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69(13):5522-5530.
30. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, et al. Mast cells and Th17 cells contribute to the lymphoma- associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2): 792-802.
31. Yan XJ, Li W, Yancopoulos S, Dozmorov I, Centola M, Allen SL, et al. Identification of distinct cytokine and chemokine clusters that correlate with outcome in B-cell chronic lymphocytic leukemia: implications for disease pathogenesis. Blood. 2010;116(21): 1368.
32. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-5456.
33. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Mast cells express IL- 17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336-3340.
34. Idler I, Giannopoulos K, Zenz T, Bhatta- charya N, Nothing M, Dohner H, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol. 2010;148(6):948-950.
35. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6): 1507-15016.
36. Zou W, Restifo NP. T(H)17 cells in tumourimmunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248-256.
37. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, et al. IL-21 mediatesapoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody dependent cellular cytotoxicity in primary chronic lymphocytic cells. Blood. 2008;111(9):4723-4730.
38. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood.2011:117(2): 563-574
39. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010;5(1):e8922